The Colorectal Cancer Diagnostics Market was valued at USD 15.2 billion in 2024, and is projected to reach USD 35.1 billion by 2034, rising at a CAGR of 8.9%. Colorectal cancer (CRC) is one of the most commonly diagnosed cancers worldwide, affecting millions of individuals each year. With CRC incidence rates rising, particularly among younger adults, the need for accurate, efficient, and early diagnostic solutions has never been more critical. Early detection significantly improves survival rates, making advanced diagnostic technologies essential for timely intervention.
The market for colorectal cancer diagnostics is expanding rapidly due to continuous advancements in imaging technologies, liquid biopsy, and AI-powered diagnostic tools. Increasing awareness campaigns and government-backed CRC screening programs across key regions are further driving demand for reliable and accessible diagnostic methods. Leading market players are actively investing in the development of high-precision, non-invasive testing solutions that cater to both clinical settings and at-home screening. The growing adoption of stool-based DNA tests, blood biomarker screenings, and AI-driven imaging solutions is revolutionizing CRC diagnostics, ensuring patients receive early and accurate assessments.
The colorectal cancer diagnostics market is segmented by test type, including blood tests, stool tests, imaging tests, biopsies, and other diagnostic methods. Imaging tests dominated the market with a 49.6% share in 2024, driven by the rising demand for early cancer detection and accurate disease assessment. Advanced imaging technologies, particularly PET-CT scans and AI-assisted radiology, play a crucial role in detecting colorectal malignancies at an early stage. These high-precision tools enhance diagnostic accuracy, facilitating personalized treatment approaches. Stool-based tests, including fecal occult blood tests and CRC DNA screenings, are also gaining traction due to their non-invasive nature, making them a preferred choice for large-scale screening programs.
The market is further categorized based on end use, with hospitals, diagnostic imaging centers, and cancer research institutions emerging as key segments. Hospitals accounted for 40.8% of the market share in 2024, primarily due to their advanced oncology and gastroenterology departments. The availability of comprehensive diagnostic facilities, skilled healthcare professionals, and integrated CRC screening programs has positioned hospitals as the leading diagnostic setting. Governments worldwide continue to implement nationwide colorectal cancer screening initiatives, further fueling hospital-based diagnostic testing.
The U.S. colorectal cancer diagnostics market generated USD 5 billion in 2024, reflecting a strong demand for early detection solutions. The rising incidence of CRC among younger populations, combined with growing awareness of the importance of early screening, is driving market expansion. The increased availability of at-home diagnostic solutions, such as blood biomarkers and stool-based tests, has made CRC screening more accessible, allowing individuals to take proactive steps toward early detection. As technological advancements continue to shape the diagnostic landscape, demand for highly accurate, non-invasive, and AI-powered colorectal cancer screening solutions is expected to surge, solidifying the U.S. as a key growth hub for the global market.
This product will be delivered within 2-4 business days.
The market for colorectal cancer diagnostics is expanding rapidly due to continuous advancements in imaging technologies, liquid biopsy, and AI-powered diagnostic tools. Increasing awareness campaigns and government-backed CRC screening programs across key regions are further driving demand for reliable and accessible diagnostic methods. Leading market players are actively investing in the development of high-precision, non-invasive testing solutions that cater to both clinical settings and at-home screening. The growing adoption of stool-based DNA tests, blood biomarker screenings, and AI-driven imaging solutions is revolutionizing CRC diagnostics, ensuring patients receive early and accurate assessments.
The colorectal cancer diagnostics market is segmented by test type, including blood tests, stool tests, imaging tests, biopsies, and other diagnostic methods. Imaging tests dominated the market with a 49.6% share in 2024, driven by the rising demand for early cancer detection and accurate disease assessment. Advanced imaging technologies, particularly PET-CT scans and AI-assisted radiology, play a crucial role in detecting colorectal malignancies at an early stage. These high-precision tools enhance diagnostic accuracy, facilitating personalized treatment approaches. Stool-based tests, including fecal occult blood tests and CRC DNA screenings, are also gaining traction due to their non-invasive nature, making them a preferred choice for large-scale screening programs.
The market is further categorized based on end use, with hospitals, diagnostic imaging centers, and cancer research institutions emerging as key segments. Hospitals accounted for 40.8% of the market share in 2024, primarily due to their advanced oncology and gastroenterology departments. The availability of comprehensive diagnostic facilities, skilled healthcare professionals, and integrated CRC screening programs has positioned hospitals as the leading diagnostic setting. Governments worldwide continue to implement nationwide colorectal cancer screening initiatives, further fueling hospital-based diagnostic testing.
The U.S. colorectal cancer diagnostics market generated USD 5 billion in 2024, reflecting a strong demand for early detection solutions. The rising incidence of CRC among younger populations, combined with growing awareness of the importance of early screening, is driving market expansion. The increased availability of at-home diagnostic solutions, such as blood biomarkers and stool-based tests, has made CRC screening more accessible, allowing individuals to take proactive steps toward early detection. As technological advancements continue to shape the diagnostic landscape, demand for highly accurate, non-invasive, and AI-powered colorectal cancer screening solutions is expected to surge, solidifying the U.S. as a key growth hub for the global market.
Comprehensive Market Analysis and Forecast
- Industry trends, key growth drivers, challenges, future opportunities, and regulatory landscape
- Competitive landscape with Porter’s Five Forces and PESTEL analysis
- Market size, segmentation, and regional forecasts
- In-depth company profiles, business strategies, financial insights, and SWOT analysis
This product will be delivered within 2-4 business days.
Table of Contents
Chapter 1 Methodology and Scope
Chapter 2 Executive Summary
Chapter 3 Industry Insights
Chapter 4 Competitive Landscape, 2024
Chapter 5 Market Estimates and Forecast, by Test Type, 2021-2034 ($ Mn)
Chapter 6 Market Estimates and Forecast, by End Use, 2021-2034 ($ Mn)
Chapter 7 Market Estimates and Forecast, by Region, 2021-2034 ($ Mn)
Chapter 8 Company Profiles
Companies Mentioned
The companies featured in this Colorectal Cancer Diagnostics market report include:- Abbott Laboratories
- Becton, Dickinson and Company
- Danaher Corporation
- Exact Sciences Corporation
- F-Hoffmann-La Roche
- Fujirebio
- GE Healthcare
- Geneoscopy
- Guardant Health
- Hologic
- NeoGenomics Laboratories
- Qiagen
- Siemens Healthineers
- Sysmex Corporation
- Thermo Fischer Scientific
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 130 |
| Published | February 2025 |
| Forecast Period | 2024 - 2034 |
| Estimated Market Value ( USD | $ 15.2 Billion |
| Forecasted Market Value ( USD | $ 35.1 Billion |
| Compound Annual Growth Rate | 8.9% |
| Regions Covered | Global |
| No. of Companies Mentioned | 16 |
